Supplemental Financial Information (Tables)

12 Months Ended

Dec. 31, 2025

Other Liabilities Disclosure [Abstract]

Schedule of Reconciliation of Cash and Cash Equivalents

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported on the consolidated balance sheets to the total of the same amounts shown on the consolidated statements of cash flows:


	As of December 31,
	2025		2024
Cash and cash equivalents	$	104,997	$	85,212
Restricted cash (included in other assets)	992		990
Total	$	105,989	$	86,202

Schedule of Reconciliation of Restricted Cash


	As of December 31,
	2025		2024
Cash and cash equivalents	$	104,997	$	85,212
Restricted cash (included in other assets)	992		990
Total	$	105,989	$	86,202

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:


	As of December 31,
	2025		2024
Prepaid expenses	$	7,174	$	7,425
Other current assets	1,511		1,079
Total	$	8,685	$	8,504

Schedule of Accounts Payable and Accrued Liabilities

Accounts payable and accrued expenses consisted of the following:


	As of December 31,
	2025		2024
Accounts payable	$	2,461	$	7,954
Accrued expenses	44,659		12,443
Third party payor reserves, short-term	4,965		10,586
Legal reserves	5,560		—
Total	$	57,645	$	30,983

Schedule of Other Current Liabilities

Other current liabilities consisted of the following:


	As of December 31,
	2025		2024
Accrued compensation	$	29,638	$	16,241
Accrued severance	771		746
Due to related parties	643		668
Current portion of long-term debt	4,542		1,211
Short-term contingent consideration liability	5,444		—
Short-term warrant liability	1,100		—
Other	4,721		1,632
Total	$	46,859	$	20,498

Schedule of Other Liabilities

Other liabilities consisted of the following:


	As of December 31,
	2025		2024
Long-term contingent consideration liability	$	1,570	$	—
Long-term warrant liability	—		3,519
Third party payor reserves, long-term	—		2,000
Other	71		—
Total	$	1,641	$	5,519

GeneDx Holdings Corp. 10-K